Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Study of Intravesical Ruvidar in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") or Patients Who Are Intolerant to BCG Therapy (Study II )

Next Previous
Trial Profile

A Phase II Clinical Study of Intravesical Ruvidar in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") or Patients Who Are Intolerant to BCG Therapy (Study II )

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TLD 1433 (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Study II
  • Sponsors Theralase Technologies

Most Recent Events

  • 27 Mar 2024 Interim results presented in the Theralase Technologies financial media release.
  • 27 Mar 2024 According to a Theralase Technologies media release, To date, Study II has provided the primary study treatment for 63 patients, with new patients being enrolled in 2Q2024.
  • 26 Mar 2024 According to a Theralase Technologies media release, the company is hosting Advisory Board meetings on April 12, 2024 and on May 4th , 2024 to present the latest Study II interim clinical data to its Principal Investigators (PIs) at the Canadian Urological Association (CUA) Bladder Cancer Forum and the American Urology Association (AUA), respectively.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top